Panelist, “Rare Disease Drug Development: Present Problems and Solutions,” Food and Drug Law Institute 2023 Annual Conference, May 17, 2023.
Speaker, “The FDCA Impact of Dobbs,” 2022 Enforcement, Litigation, and Compliance Conference: For the Drug, Device, Food, and Tobacco Industries, Food and Drug Law Institute, December 7, 2022.
Moderator, “Updates in Orphan Drug Regulation and Litigation,” Food and Drug Law Institute, June 15, 2022.
Speaker, “Breaking New Ground: Innovations in Alzheimer’s Research,” The Hill, March 2, 2022.
Panelist, Strategies to Support Rare Disease Product Development During COVID-19, Rare Disease Day 2021, FDA, March 5, 2021.
Speaker, Rare Disease Day, National Institutes of Health (NIH), March 1, 2021.
Speaker, Rare Disease Policy Webinar, MDA Advocacy Institute, February 25, 2021.
Moderator, COVID-19 Vaccines Update: FDA and CDC Leaders Address the Rare Disease Community, NORD, January 15, 2021.
Moderator, Perspectives From The Hill: The Year to Date and What’s Ahead, Rare Diseases and Orphan Products Breakthrough Summit, NORD, October 8, 2020.
Speaker, Webinar On Resilience Approach Towards Rare Disease Policy In India, People to People Health Foundation (PPHF) and GRID Council, August 4, 2020.
Speaker, Public Meeting on the Reauthorization of the Prescription Drug User Fee Act (PDUFA), FDA, July 23, 2020.
Speaker, FDLI Annual Conference: Exploring Advanced Topics in Food and Drug Law, Food and Drug Law Institute, May 2, 2019.
Panelist, Tissue Agnostic Therapies: Regulatory Considerations for Orphan Drug Designation; Public Workshop, FDA, May 9, 2018.
Panelist, Updating Outdated Product Labels, Friends of Cancer Research Annual Meeting, Friends of Cancer Research, November 15, 2017.
Panelist, Market Access, Market Success, 2017 Leading on Biosimilars Conference, AAM, September 12, 2017.
Panelist, Developing a National Registry of Pharmacologic and Biologic Clinical Trials, Committee on Clinical Trial Registries, Board on Health Sciences Policy, Institute of Medicine, June 27, 2005.